Rare diseases
Investigational molecules
Locations
Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus
BulgariaSwitching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study
FranceStudy comparing ALG-000184 with tenofovir disoproxil in untreated adults with chronic hepatitis B virus infection
BulgariaStudy on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment
CzechiaStudy on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis
AustriaStudy Comparing Doravirine and Dolutegravir-Based Treatments for People with HIV-1 Who Have Not Yet Started Therapy
FranceStudy on the Effectiveness of Doravirine, Tenofovir Disoproxil, and Lamivudine in HIV Patients with M184V/I Mutation and Controlled Viral Load
FranceStudy on the Effects and Safety of Bulevirtide, Peginterferon Alfa-2a, and Entecavir in Patients with Chronic Hepatitis D
SwedenPhase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease
CzechiaPhase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus
BulgariaStudy on Stopping Tenofovir Alafenamide, Tenofovir Disoproxil, and Entecavir in Patients with Chronic Hepatitis B
BelgiumStudy Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load
GermanyTell us about your condition – we search every trial in Europe and connect you with the right site.
